Last reviewed · How we verify
Salmeterol MDI
Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Salmeterol MDI |
|---|---|
| Also known as | Serevent |
| Sponsor | Sumitomo Pharma America, Inc. |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Salmeterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and sustained bronchodilation. Its lipophilic properties allow it to partition into airway tissue, providing a depot effect that extends its duration of action to approximately 12 hours, making it suitable for twice-daily dosing in chronic obstructive airway diseases.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
- Asthma Research in Children and Adolescents
- Salmeterol Effect on Exercise Performance (NA)
- Urinary Concentration After Salmeterol (NA)
- Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability. (NA)
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
- Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139) (PHASE3)
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Mechanism(s) of Airflow Limitation During Exacerbation of Asthma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salmeterol MDI CI brief — competitive landscape report
- Salmeterol MDI updates RSS · CI watch RSS
- Sumitomo Pharma America, Inc. portfolio CI